

Administration

- 1. True
- 2. New
- 3. False
- 4. The Physician
- 5. Carboplatin
- 6. Area Under the Curve / Drug Exposure
- 7. True
- 8. Three Months
- 9. True
- 10. Vesicant; 3
- 11. True
- 12. True
- 13. Bedside / Chairside
- 14. Central Line
- 15. Friends
- 16. 3; 7
- 17. False

Alkylating Agents

- 1. Dividing
- 2. Dividing
- 3. Nausea, Vomiting, Myelosuppression, Infertility, Hypersensitivity Reactions, Alopecia, Secondary Malignancies, Tumor Lysis Syndrome, Pregnancy Category D
- 4. Nitrosureas
- 5. Sterile Alcohol
- 6. Calvert
- 7. True
- 8. Carmustine (BCNU)
- 9. Busulfan
- 10. True
- 11. Ifosfamide
- 12. Busulfan
- 13. Cisplatin; Carboplatin; Oxaliplatin
- 14. Highly
- 15. Nephrotoxicity
- 16. False
- 17. True
- 18. Increases

- 19. Neurotoxicity
- 20. Oxaliplatin; Acute Neurotoxicity
- 21 True
- 22. Electrolyte Wasting, Nausea/Vomiting, Nephrotoxicity, Ocular Toxicity, Ototoxicity, Peripheral Neuropathy, Transient elevations of Liver Function Tests (LFT)

Antimetabolites

- 1. Myelosuppression, Mucositis, GI Symptoms, Liver Dysfunction
- 2. True
- 3. 24 Hours
- 4. Vitamin B12; Folic Acid
- 5. True
- 6. Uridine Triacetate (Vistogard)
- 7. False
- 8. Enhance
- 9. Increases
- 10. True
- 11. Within 30 Minutes
- 12. True
- 13. Myelosuppression, Hand-Foot Syndrome, Cardiac, GI, Epithelial Ulceration, Hyperbilirubinemia
- 14. False
- 15. Cerebellar Toxicity
- 16. Myelosuppression
- 17. Radio sensitizer
- 18. Infection
- 19. True

Antitumor Antibiotics

- 1. Anthracyclines, Miscellaneous Agents
- 2. Cardiac
- 3. MUGA/ECHO
- 4. Dexrazoxane (Totect)
- 5. Red
- 6. Blue
- 7. Cool
- 8. Cardiac
- 9. SOB, Decrease in Activity, Peripheral Edema, Enlarged Heart
- 10. Zinecard
- 11. Myelosuppression, Nausea, Vomiting, Alopecia, Mucositis, Infertility

- 12. 300-550 mg/m2
- 13. Bleomycin
- 14. PFTs; PFTs

CAR-T Therapy

- 1. False
- 2.T-Cell
- 3. Cytokine release syndrome (CRS)
- 4. Administration of Tocilizumab, corticosteroids, fluid resuscitation, vasopressors
- 5. Cytokine release syndrome, electrolyte imbalances, hypertension, neurotoxicity

Chemotherapy Error Prevention

- 1. Cannot
- 2. Fatigue, Lack of Knowledge, Stress, Understaffing, Poor Communication, Human Error, Environmental Factors
- 3. Prevent
- 4. False
- 5. Patient
- 6. Document the Spill
- 7. False
- 8. False
- 9. Chemotherapy
- 10. Any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in control of the healthcare provider, patient, or consumer
- 11. Multidrug Protocols with Varied Schedules and Routines, Narrow Therapeutic Index and Toxicity within Therapeutic Ranges, Complex Regimens, Vulnerable Patient Population

Extravasation

- Absence of Blood Return, Swelling, Erythema, Inflammation, Leaking at Catheter Entrance Site, Pain, Burning, Stinging
- 2. Some
- 3. True
- 4. Stop the Administration
- 5. Vesicant
- 6. Flushes; Blood Return
- 7. True
- 8. Oxaliplatin, Cisplatin, Adriamycin, Epirubicin, Dactinomycin, Daunorubicin, Idarubicin, Doxil, Mitoxantrone
- 9. True
- 10. False

- 11. Antitumor Antibiotic; IV
- 12. False

Genetics and Genomics

- 1. Genomics
- 2. True
- 3. Ethnicity, Multiple Family Members with Cancer, Rare Cancers, Several Generations of Cancer
- 4. Germline

Growth Factors

- 1. Myelosuppression
- 2. Neutropenia; Anemia; Thrombocytopenia
- 3. True
- 4. Absolute Neutrophil Count
- 5. ANC = Total WBC X (Segs + Bands) /100
- 6. Slight; Minimal; Moderate; Severe
- 7. GCSF
- 8. False
- 9. Bone Pain
- 10. Neutrophil; Macrophage
- 11. CBC
- 12. Kidneys
- 13. Myeloid
- 14. Thrombocytopenic
- 15. Bone pain

Hormonal Agents

- 1. False
- 2. True
- 3. Selective Estrogen Receptor Modulator, Selective Estrogen Receptor Downregulator; Aromatase Inhibitor
- 4. Fluvestrant SERD; Tamoxifen SERM; Anastrozole Al
- 5. Tamoxifen blocks the effects of estrogen in breast tissue. It acts as an estrogen agonist in the uterus, bone, and lipid tissue.
- 6. Thromboembolic Events, Uterine Malignancies, Ocular Effects, Menopausal Symptoms, Weight Gain or Loss, Mood Swings, and Weakness
- 7. True
- 8. True
- 9. True
- 10. Gynecomastia, Hot Flashes, Fatigue, Depression, Erectile Dysfunction, Edema, Injection Site Reactions
- 11. Antiandrogens block the effects of androgen in the prostate.

- 12. True
- 13. True
- 14. Post

Hypersensitivity Reactions

- 1. True
- 2. Adaptive
- 3. Platinums
- 4. True
- 5. Rituximab, Cetuximab, Alemtuzumab, Gemtuzumab, Ofatumumab, Trastuzumab
- 6. Cycle 1 or 2

Interferons, Interleukin 2, L-asparaginase, and Vaccine Therapy

- 1. Tumor
- 2. Cytokine Induced Capillary Leak Syndrome, Increased Liver Function, Pruritis, Flu-Like Symptoms, Neurotoxicity, Infection, Oliguria, Increased Creatinine, Nausea, Vomiting, and Diarrhea
- 3. Hypotension; Tachycardia; Fever; Chills
- 4. CBC with Diff, CMP, Weight, Strict I/O
- 5. False
- 6. L-asparagine
- 7. False
- 8. Pancreatitis, Hepatitis, Anaphylaxis, DIC, Fever
- 9. Attachment of a PEG to a drug or therapeutic protein can "mask" the agent from the hosts' immune system, decreasing immunogenicity and subsequent reactions.
- 10. Fibrinogen
- 11. Vaccine; PAP-GM-CSF
- 12. Melanoma

Miscellaneous Drugs

- 1. False
- 2. EKG
- 3. Calcium; Potassium; Magnesium
- 4. True
- 5. APL Differentiation Syndrome
- 6. Steroids
- 7. CBC; Hepatic Function
- 8. mTOR; With or Without
- 9. Impaired Wound Healing
- 10. B

Monoclonal Antibodies

- 1. A; D; B; C
- 2. False
- 3. True
- 4. False
- 5. Murine; Chimeric; Humanized; Fully Human
- 6 True
- 7. Ramucirumab, Ziv-Aflibercept
- 8. Acneiform
- 9. True
- 10. Cytokine Release Syndrome; Neurological Toxicities
- 11. Breast; HER 2
- 12. Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab, and Ipilimumab
- 13. True

Organ Toxicities

- 1. Acute, Delayed, Anticipatory
- 2. Volume
- 3. 40%
- 4. Pain Management, Mouth Care Before and After Meals, Rinsing Mouth with Normal Saline, Water-Based Moisturizers to Protect Lips, Patient Education Including Proper Oral Hygiene and Avoiding Tobacco and Alcohol
- 5. Age, Pre-Existing Cardiac Conditions, Cumulative Drug Dose, Radiation to Chest, Receiving Multiple Cardio-Toxic Drugs, HSCT, Host Susceptibility, Hepatic or Renal Dysfunction, Smoking, Diabetes
- 6. Zinecard
- 7. Anthracyclines
- 8. 400
- 9. False
- 10. Myelosuppression
- 11. Nausea
- 12. Mesna
- 13. True
- 14. True

Plant Alkaloids

- 1. Vincristine
- 2. Stocking/Glove, Neuropathic Pain, Autonomic Dysfunction, Constipation

- 3. Liver; Hepatic
- 4. False
- 5. True
- 6. True
- 7. Early Atropine (Lomotil); Late Imodium
- 8. Hypotension
- 9. Wheezing, Bronchospasm, Hypotension
- 10. False
- 11. B and C
- 12. Antihistamine; Steroid; H2 Blocker; Anti-Emetic
- 13. A, B, and C

Principles of Cancer Drug Therapy

- 1. Monotherapy; Combination Therapy
- 2. Cytotoxic
- 3. Innate
- 4. Tumor cells can become resistant to single agent dosing and combination therapy has more efficacious dosing and differing mechanisms of action and toxicity patterns.
- 5. Resistance
- 6. True
- 7. Decreasing
- 8. Alkylating agents, anthracyclines

Protectants

- 1. Leucovorin, Dexrazoxane, Amifostine, Palifermin, Mesna
- 2. Leucovorin
- 3. Leucovorin
- 4. Heart
- 5. Bone Marrow
- 6. Radiation
- 7. Bladder
- 8. Ifosfamide
- 9. True
- 10. Leukovorin

Tyrosine Kinase Inhibitors

- 1. True
- 2. CYP3A4; CYP3A4
- 3. False

- 4. False
- 5. Hepatic
- 6. Weight Gain, Shortness of Breath, Ankle Swelling
- 7. True
- 8. Empty
- 9. Diarrhea
- 10. Blood Pressure
- 11. True
- 12. RET, MET, VEGFR, KIT, and FLT-3
- 13. True
- 14. D
- 15. Imatinib, Regorafenib, Alectinib, Midostaurin
- 16. Erlotinib, Sorafenib, Lapatanib, Nilotinib, Pazopanib, Cabozantinib, Dabrafenib, Trametinib, Afatinib, Ceritinib